One thing mentioned in the article is the lack of patent incentives for Enbrel that don't affect the other medication with the funky Xanjy name that appears to have longer patent legs. If true the patent system is sick and twisted and needs to be turned 180 degrees to where the invention owner incurs disincentives - say loss of 1/4 of the exclusivity period - for each failure to share material research surrounding patented formulations.